Abnormal DNA Methylation Induced by Hyperglycemia Reduces CXCR4 Gene Expression in CD34\(^+\) Stem Cells

Vera Vigorelli, MS; Jessica Resta, MS; Valentina Bianchessi, MS; Andrea Lauri, PhD; Beatrice Bassetti, MS; Marco Agrifoglio, MD; Maurizio Pesce, PhD; Gianluca Polvani, MD; Giorgia Bonalumi, MD; Laura Cavallotti, MD; Francesco Alamanni, MD; Stefano Genovese, MD; Giulio Pompilio, MD, PhD; Maria Cristina Vinci, PhD

**Background**—CD34\(^+\) stem/progenitor cells are involved in vascular homeostasis and in neovascularization of ischemic tissues. The number of circulating CD34\(^+\) stem cells is a predictive biomarker of adverse cardiovascular outcomes in diabetic patients. Here, we provide evidence that hyperglycemia can be "memorized" by the stem cells through epigenetic changes that contribute to onset and maintenance of their dysfunction in diabetes mellitus.

**Methods and Results**—Cord-blood–derived CD34\(^+\) stem cells exposed to high glucose displayed increased reactive oxygen species production, overexpression of p66\(^{shc}\) gene, and downregulation of antioxidant genes catalase and manganese superoxide dismutase when compared with normoglycemic cells. This altered oxidative state was associated with impaired migration ability toward stromal-cell–derived factor 1 alpha and reduced protein and mRNA expression of the C-X-C chemokine receptor type 4 (CXCR4) receptor. The methylation analysis by bisulfite Sanger sequencing of the CXCR4 promoter revealed a significant increase in DNA methylation density in high-glucose CD34\(^+\) stem cells that negatively correlated with mRNA expression (Pearson \(r=-0.76; P=0.004\)). Consistently, we found, by chromatin immunoprecipitation assay, a more transcriptionally inactive chromatin conformation and reduced RNA polymerase II engagement on the CXCR4 promoter. Notably, alteration of CXCR4 DNA methylation, as well as transcriptional and functional defects, persisted in high-glucose CD34\(^+\) stem cells despite recovery in normoglycemic conditions. Importantly, such an epigenetic modification was thoroughly confirmed in bone marrow CD34\(^+\) stem cells isolated from sternal biopsies of diabetic patients undergoing coronary bypass surgery.

**Conclusions**—CD34\(^+\) stem cells “memorize” the hyperglycemic environment in the form of epigenetic modifications that collude to alter CXCR4 receptor expression and migration. *(J Am Heart Assoc. 2019;8:e010012. DOI: 10.1161/JAHA.118.010012.)*

**Key Words:** cardiovascular complications • CD34 stem cells • CXCR4 • diabetes mellitus • DNA methylation • histone modifications • metabolic memory

---

Diabetes mellitus (DM) is a chronic and complex disease characterized by hyperglycemia and associated with a broad spectrum of micro- and macrovascular complications that constitute a major health burden in Western countries.\(^1\)

Despite the progresses of pharmacological therapy, the cellular and molecular mechanisms underlying diabetic complications are not entirely understood and the associated cardiovascular risk is still far from eliminated.\(^2,3\)

Endothelial dysfunction induced by hyperglycemia is recognized as the major causal factor in the development and progression of diabetic vascular complications. Since the early 2000s, numerous studies showed a linear correlation between the decline in number and function of circulating progenitor cells such as CD34\(^+\) cells, severity of diabetic disease, and presence of vascular complications.\(^4,5\) CD34\(^+\) stem cells are bone marrow (BM)-derived stem cells, both representative for hematopoietic stem cells and endothelial progenitor cells contributing to preservation of an intact endothelial layer and neovascularization of ischemic tissues.\(^6,7\) The dramatic numeric and functional decay of these cells in the diabetic metabolic environment\(^8,9\) is linked to severe endothelial dysfunction and elevated risk of adverse cardiovascular events. Consistently, level of the circulating
Clinical Perspective

What Is New?

- Human CD34+ stem cells “memorize” metabolic stress in the form of epigenetic changes that contribute to the self-perpetuating alteration of gene expression.
- Epigenetic mechanisms might contribute to C-X-C chemokine receptor type 4/stromal-cell–derived factor 1 alpha axis impairment of CD34+ stem cells in diabetic patients, which has a critical function in revascularization processes.

What Are the Clinical Implications?

- Epigenetic mechanisms contribute to the self-perpetuating alterations of genes involved in progenitor cell function, with direct implications on tissue homeostasis and repair in diabetes mellitus.
- Presence of molecular modifications potentially inherited by daughter cells dramatically reduce the translational potential of these cells in regenerative medicine.
- Investigation of epigenetic mechanisms underlying metabolic memory may be relevant in understanding the barriers that prevent the pharmacological regression of diabetes mellitus cardiovascular complications despite optimal management of hyperglycemia.

CD34+ stem cell population has recently proved to be an efficient clinical-grade–independent biomarker of cardiovascular risk in diabetic patients, capable of predicting long-term development or progression of microangiopathy and cardiovascular events in type 2 DM (T2DM).

A consistent body of literature has shown that diabetic patients can develop diabetic vascular complications even after intensive glycemic control, a phenomenon known as “metabolic memory.” Hyperglycemia appears to be remembered in organs, such as blood vessels, heart, kidneys, and eyes, and the underlying mechanisms seem to rely on epigenetics. Epigenetics plays a critical role in regulating tissue-specific gene expression; hence, alterations in its mechanisms may induce long-term changes in gene function and metabolism, which can persist after the return to normality. Mechanistically, recent studies clearly indicated that DM drives epigenetic changes, such as DNA methylation and histone modifications, that result in aberrant and long-lasting expression of pathological genes in a plethora of cell types, such as vascular smooth muscle cells, endothelial cells, and leukocytes, which may play a substantial role in the pathophysiology of vascular complications associated with DM. Persistence of functional defects in a variety of progenitor cell populations, described in both preclinical and human DM after glucose normalization, suggests the presence of this phenomenon also in stem cells. However, to date, no studies have established, at a single-gene level, the implication of epigenetic mechanisms in hyperglycemia-induced dysfunction of CD34+ stem cells. Here, we investigated, by an in vitro model, whether epigenetic mechanisms contribute to C-X-C chemokine receptor type 4 (CXCR4)/stromal-cell–derived factor 1 alpha (SDF-1α) axis impairment, which has a critical function in revascularization processes, in diabetic patients.

We show, for the first time, that umbilical cord blood (UCB)-derived CD34+ stem cell alterations induced in vitro by hyperglycemia are not completely reversible and that epigenetic modifications resulting from high-glucose (HG) challenge are involved in persistent downregulation of the CXCR4 gene and impaired migratory capacity despite recovery to normoglycemia (NG). Moreover, we have confirmed identical epigenetic findings in BM-CD34+ stem cells isolated from sternal biopsies from diabetic patients undergoing coronary bypass surgery.

Methods

The data that support the findings of this study are available from the corresponding author upon reasonable request. Additional methods can be found in Data S1.

Study Design

We aimed the present study at investigating the epigenetic mechanisms contributing to the dysfunctional phenotype of CD34+ stem cells in diabetic patients. To avoid readout misinterpretations derived from aging or other risk factors, we first evaluated the effects of HG on the epigenetic makeup of naive UCB-derived CD34+ stem cells (Figure 1). This allowed the discrimination between epigenetic modifications established as a direct consequence of hyperglycemia exposure, rather than those related to confounding variables such as age and cardiovascular risk factors. As depicted in Figure 1, we expanded CD34+ stem cells in HG conditions until CD34+ stem cells lost glucose tolerance. Afterward, in order to reproduce metabolic memory in vitro, cells were recovered in NG for 3 days, as previously described. We then performed molecular and epigenetic analyses of the gene(s) involved in CD34+ stem cell dysfunction upon HG and NG recovery. Results have been validated in BM-derived CD34+ stem cells isolated from patients with coronary artery disease (CAD).±DM.

Study Participants

All experiments have been carried out upon approval of local ethic committees (No. 2015/ST/232 and R196/14—CCM
Informed written consent was obtained from all patients before BM harvesting. CAD (n=7) and CAD-DM (n=7) subjects have been selected by stringent matching of: age, pharmacological treatments, and major risk factors. At admission, CAD-DM patients were treated with sulfonylureas or metformin±insulin. Clinical characteristics of patients are shown in Table.

Table. Clinical Characteristics of Patients

<table>
<thead>
<tr>
<th></th>
<th>CAD (n=7)</th>
<th>CAD-DM (n=7)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>64±4</td>
<td>68±3</td>
<td>0.44</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.7±1.1</td>
<td>25.6±0.7</td>
<td>0.41</td>
</tr>
<tr>
<td>Glycemia, mg/dL</td>
<td>110±3</td>
<td>162±13*</td>
<td>0.0021</td>
</tr>
<tr>
<td>LDL, mg/dL</td>
<td>112±18</td>
<td>91±15</td>
<td>0.39</td>
</tr>
<tr>
<td>HDL, mg/dL</td>
<td>42±4</td>
<td>50±5</td>
<td>0.27</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>176±21</td>
<td>162±15</td>
<td>0.6</td>
</tr>
<tr>
<td>Cardiovascular comorbidities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension (n)</td>
<td>5</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Dyslipidemia (n)</td>
<td>4</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Glucose-lowering drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin (n)</td>
<td>0</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Oral antidiabetic drug (n)</td>
<td>0</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Other therapies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antihypertensive drugs (n)</td>
<td>3</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Lipid-lowering drugs (n)</td>
<td>4</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

CAD±DM, coronary artery disease with or without diabetes mellitus; BMI indicates body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

*P<0.01 vs CAD.

UCB CD34+ Stem Cell Isolation and Expansion

UCB was collected from the umbilical cord of healthy full-term deliveries. CD34+ stem cells were isolated and expanded as previously described, with some slight modification. Briefly, mononuclear cell fraction was isolated from UCB by density gradient centrifugation using Ficoll-Paque (Lymphoprep; Sentinel Diagnostics, SpA, Milan, Italy). CD34+ stem cells were then magnetically sorted from the mononuclear cell fraction using the MidiMACS system (CD34 Microbead Kit; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Isolated cells were expanded up to 20 days in SFEM medium (Voden Medical Instruments, SpA, Meda, Italy) containing 20 ng/mL of interleukin-6, 20 ng/mL of interleukin-3, 50 ng/mL of fms-like tyrosine kinase 3, and 50 ng/mL of stem cell factor (PeproTech EC Ltd., London, UK), in hyperglycemic (30 mmol/L of glucose; HG) and normoglycemic (30 mmol/L of mannitol; NG) conditions. To reproduce the metabolic memory phenomenon in vitro, HG-CD34+ stem cells were returned to physiological glucose conditions for 3 days (exHG-CD34+), as previously described.22

DOI: 10.1161/JAHA.118.010012
Sternal BM Biopsy and CD34⁺ Stem Cell Isolation

Sternal blood from the BM of 14 patients with CAD±DM was obtained by needle aspiration. Aspirates were suspended in saline buffer. Mononuclear cell fraction as well as CD34⁺ stem cells were isolated as aforementioned.

CD34⁺ Stem Cell Growth Curves

CD34⁺ stem cells were seeded at an initial density of 2.0 × 10⁵ cells/well and cultured for up to 30 days in HG and NG conditions. Cells were counted on days 10, 20, and 30.

Migration Assays

Cell migration was determined by the use of Transwell culture inserts (5-µm pore membrane; Corning Incorporated, Corning, NY), according to the manufacturer’s instructions. In brief, 1 × 10⁵ cells/well CD34⁺ stem cells were seeded onto the upper chamber and allowed to migrate toward the lower chamber containing, or not, SDF-1α (50 ng/mL; PeproTech EC Ltd.). Transwells were incubated at 37°C, 5% CO₂, for 4 hours. Migrated cells were counted and results are expressed as a migration index.

Flow Cytometric Assays

CD34⁺ stem cells were incubated for 30 minutes with allophycocyanin-conjugated monoclonal antihuman CXCR4 antibody (BD Biosciences, San Jose, CA), Annexin V (BD Biosciences), and a CellROX green antibody (BD Biosciences), and a CellROX green fluorescent assay kit (Life Technologies Italia, Monza, Italy) for detection of the CXCR4 receptor, early apoptosis, and reactive oxygen species (ROS), respectively. The Becton-Dickinson FACScalibur platform (Becton-Dickinson, Franklin Lakes, NJ) was used to analyze samples by use of appropriate physical gating. At least 10⁶ events in the indicated gates were acquired.

Western Blot Analyses

Protein kinase B (AKT) phosphorylation was evaluated by stimulating for 15 minutes CD34⁺ stem cells (1.2 × 10⁵/sample) with 50 ng/mL of SDF-1α. Cells were then lysed in Laemmli buffer and 30 µL of proteins resolved on 10% SDS-PAGE. Whole-cell lysate (80 µg) was used to evaluate manganese superoxide dismutase, catalase, p66shc, DNA methyltransferase 1 (DNMT1), and DNA methyltransferase 3B (DNMT3B) expression. Proteins were transferred to PVDF membranes (Millipore, Merck SpA, Milan, Italy) and then incubated with the relevant primary antibody (Table S1). After washing, membranes were incubated with secondary antibody, which was linked to horseradish peroxidase (Pierce Antibody; Pierce Biotechnology, Rockford, IL) and revealed by ECL detection (Pierce). Results were quantified using the Alliance 9.7 Western Blot Imaging System 8 (UVitec Ltd., Cambridge, UK).

DNA Extraction and Bisulfite Modification

Genomic DNA was isolated by the PureLink Genomic DNA kit (Invitrogen, Carlsbad, CA), following the manufacturer’s protocols. Nucleic acid samples were quantified by NanoDrop, and integrity was analyzed by 1% agarose gel electrophoresis. Bisulfite conversion and subsequent purification was performed with the MethylCode Bisulfite Conversion Kit (Invitrogen), starting from 300 ng of total DNA.

RNA Extraction, cDNA Preparation, and Quantitative Polymerase Chain Reaction Reactions

Total RNA from CD34⁺ stem cells was isolated by use of the Directzol RNA Kit (Zymo Research, Irvine, CA), following the manufacturer’s protocols. Total RNA (500 ng) was converted to cDNA with the Superscript III kit (Life Technologies, Carlsbad, CA), according to the manufacturer’s protocol. Retrotranscribed RNA was used to quantify gene expression. Data, expressed as fold-change (2⁻ΔΔCT) over NG after normalization to each housekeeping gene, were log2 transformed before analysis. Primers are reported in Table S2. All reactions were performed with SYBR Green Supermix 2X (Bio-Rad Laboratories, Hercules, CA) on CFX96 Real-Time System PCR (Bio-Rad).

Quantitative Polymerase Chain Reaction Analysis of CXCR4 Promoter Methylation

Methylation of the CXCR4 promoter was evaluated on bisulfite-treated DNA by “2-step SYBR Green-based polymerase chain reaction (PCR),” a new technique devised by our laboratory and described in detail by Bianchessi et al.24

CXCR4 Promoter Sequencing

The CXCR4 promoter was amplified from bisulfite-treated DNA as previously described.24 Converted DNA was cloned into the pCR4-TOPO-TA cloning vector (Invitrogen) and transformed in Escherichia coli strain DH5α. Ten colonies for each sample were randomly picked and directly used for PCR amplification to verify vector insertion by T3 and T7 primers. PCR products were Sanger sequenced with the T3 primer with the help of an external service (GATC Biotech, Konstanz, Germany). Alignment (multiple sequence ClustalW alignment) and analysis of sequences was performed with
BioEdit software and data analyzed and represented by QUMA software (http://quma.cdb.riken.jp/) for CpG methylation and Methtools 2.05 (http://genome.imbjen.de/methtools/) for non-CpG methylation.

### Evaluation of Bisulfite Conversion Efficiency and Normalization of Non-CpG Methylation

Genomic DNA extracted from primary UCB-derived CD34+ stem cells was whole-genome amplified by using the REPLi-g Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer’s protocol. The whole-genome amplified product was purified by the QIAquick PCR Purification Kit (Qiagen) and quantified with NanoDrop. The whole-genome amplified product was used as fully unmethylated DNA.25 After bisulfite conversion, the CXCR4 promoter was amplified, cloned, and Sanger sequenced as before.24 Results were analyzed by Methtools 2.05 software and used for normalization of non-CpG methylation data with the formula:

\[
\text{Sample nonCpG\%} = \frac{\text{WGA nonCpG\%}}{\text{WGA nonCpG\%}} \times 100
\]

### Chromatin Immunoprecipitation Assays

Treated cells were washed and cross-linked using 1% formaldehyde for 20 minutes. After stopping cross-linking by addition of 0.1 M of glycine, cell lysates were sonicated with Episonic 2000 (Epigentek Group Inc., Farmingdale, NY) and centrifuged for 10 minutes at 10 000g. Supernatants were immunoprecipitated using the Epitect ChIP OneDay Kit (Qiagen), following the manufacturer’s protocols. The list of antibodies used is reported in Table S1. Recovered DNA fragments were amplified for the CXCR4 gene by qPCR with 3 couples of primers spanning 3 different regions of the gene. qPCR values were normalized to input DNA and to the values obtained with immunoglobulin G isotype. The data are expressed as fold-change over NG.

### Statistical Analysis

Results are given as mean±SEM. All experiments were performed at least in triplicate, unless stated otherwise. All data expressed as fold-change were log2-transformed before analysis. The data were tested for the normality by using the Shapiro–Wilk normality test. Differences between data were evaluated by paired or unpaired Student t test (2-group comparisons), 1-way, 2-way repeated-measures ANOVA followed by the post-hoc Newman–Keuls multiple comparison test, as appropriate. Correlations were calculated using Pearson’s coefficient. A value of P≤0.05 was considered significant.

All statistical analysis was performed using GraphPad Prism software (GraphPad Software Inc., La Jolla, CA).

### Results

#### HG Affects Proliferation and Oxidative State of CD34+ Stem Cells

In order to establish standard conditions under which HG effects may be reliably reproduced in vitro, cells were cultured in 30 mmol/L of glucose and counted after 10, 20, and 30 days. The analysis of cellular growth curves revealed significant differences between HG-CD34+ and NG-CD34+ stem cells. Twenty days after seeding, HG-CD34+ stem cells showed a significant decrease in proliferation rates when compared with their osmotic controls (30 mmol/L of mannitol; Figure 2A). This loss of glucose tolerance was associated with a significant increase in mitochondrial ROS production (Figure 2B and 2C). Consistently, we found a significant reduction of the antioxidant enzymes, catalase and manganese superoxide dismutase, expression (Figure 3A, 3B, 3D, and 3E), whereas p66shc, a gene involved in ROS generation and linked to hyperglycaemic memory, was upregulated (Figure 3C and 3F).

#### HG Induces Persistent Impairment of CXCR4/SDF-1α Axis in CD34+ Stem Cells

The CXCR4/SDF-1α axis is primarily involved in CD34+ stem cell mobilization and migration from the BM to sites of ischemia and endothelial injury.27 A large body of evidence shows that expression and downstream pathways of CXCR4 receptor are impaired in diabetic patients.28–30 In our hands, after 20 days, HG-CD34+ stem cells exhibited a significant reduced migration toward human recombinant SDF-1α (50 ng/mL; Figure 4A). The analysis of CXCR4 downstream signaling by western blot revealed a significant decrease of AKT phosphorylation in HG-CD34+ stem cells after SDF-1α stimulation (Figure 4B and 4C). In addition, expression of CXCR4, both at mRNA and protein levels, was also found to be significantly downregulated, as assessed by qPCR and flow cytometry, respectively (Figure 4D through 4F). Taken together, these findings indicated that an HG challenge induces a profound SDF-1α/CXCR4/phosphoinositide 3-kinase/AKT signaling pathway impairment in naïve UCB-derived CD34+ stem cells. Notably, upon recovery for 3 days in NG conditions, CD34+ stem cells (exHG-CD34+ stem cells) still displayed functional and molecular alterations (Figure 4A through 4F), which was associated with enduring high ROS production (Figure S1). These data represent the first evidence of in vitro–induced metabolic memory in naïve CD34+ stem cells.
HG Increases DNA Methylation of the CXCR4 Promoter in CD34+ Stem Cells

Numerous studies in tumor biology have demonstrated that DNA methylation, an epigenetic modification associated with gene silencing, regulates CXCR4 expression in cancer cells.\textsuperscript{31-33} We therefore postulated that such a repressive epigenetic modification was also involved in the downregulation of CXCR4 mRNA in HG-CD34+ stem cells. Thus, we evaluated the CpG methylation status (5mCpG) of a region of the CXCR4 gene promoter encompassing \textsuperscript{1349} to \textsuperscript{738} nucleotides relative to the \textsuperscript{1} transcription start site.

Figure 2. Effect of HG on proliferation and oxidative state of CD34\textsuperscript{+} stem cells. A, Proliferation curves of CD34\textsuperscript{+} stem cells exposed to HG concentrations (30 mmol/L; n=6; *\textit{P}<0.05; **\textit{P}<0.01; 2-way rmANOVA). B, Flow cytometric quantification of ROS production in HG-treated cells. Data are reported as log\textsubscript{2} fold-change (FC) of MFI over control (NG; n=6; **\textit{P}<0.01 vs NG; paired t test). C, Representative flow cytometry histograms of ROS quantification. HG indicates high glucose; MFI, mean fluorescence intensity; NG, normal glucose; ROS, radical oxygen species.

Figure 3. Effect of HG on antioxidant gene expression in CD34\textsuperscript{+} stem cells. A through C, Expression of MnSOD, CAT, and p66\textsubscript{shc} genes evaluated by qPCR. Data are from at least 6 independent experiments (*\textit{P}<0.05; **\textit{P}<0.01 vs NG; paired t test) and are expressed as log\textsubscript{2} fold-change (FC). D through F, Evaluation of MnSOD, CAT, and p66\textsubscript{shc} protein expression by western blot. Analysis of at least 3 independent experiments. Data after loading normalization (\textbeta-actin) are expressed as log\textsubscript{2} FC over control (NG; *\textit{P}<0.05; **\textit{P}<0.01 vs NG; paired t test). G, Representative immunoblot images are shown. CAT indicates catalase; HG, high glucose; MnSOD, manganese superoxide dismutase; NG, normal glucose; p66\textsubscript{shc}, Src homolog and collagen homologs (shc) adaptor protein.
Bisulfite-treated DNA from HG and NG-CD34+ stem cells was first analyzed for CXCR4 methylation density by a 2-step qPCR methylation method. This assay, designed in our laboratory for the quantitative evaluation of DNA methylation status of genes,24 showed a significant increase of CXCR4 promoter methylation in HG-CD34+ stem cells (Figure 5B). Results were then validated by bisulfite Sanger sequencing, the “gold-standard” technology for DNA methylation studies. In accord with our method, bisulfite sequencing gave similar readouts (Figure 5C and 5D). Remarkably, after normalization against bisulfite conversion efficiency, sequencing data analysis by Methtools 2.05 (http://genome.imbiena.de/methtools/) revealed a 1.8-fold increase of non-CpG methylation (5mCpN) in HG-CD34+ stem cells when compared with NG-CD34+ stem cells (Figure 5E and 5F).

Notably, both CpG and non-CpG methylation changes, although the latter did not reach statistical significance, were still present after 3-days in NG concentrations (exHG-CD34+ stem cells; Figure 5B through 5F).

**Increased DNA Methylation Associates With a More-Inactive Chromatin Conformation and Reduced Engagement of RNA Polymerase II to the CXCR4 Promoter**

DNA methylation and histone modification systems are highly inter-related and mechanistically rely on each other for...
CXCR4 Gene Methylation in Diabetic CD34+ Stem Cells

Vigorelli et al

ORIGINAL RESEARCH

A

(CXCR4 Chr2: 136,11-136,12 Mb)

Promoter

GpG island

Analyzed region

B

TWO-STEP qPCR

C

SANGER SEQUENCING

D

SANGER SEQUENCING

E

non - CpG Methylation

F

SANGER SEQUENCING

DOI: 10.1161/JAHA.118.010012

Journal of the American Heart Association
chromatin function. Hence, we evaluated whether increased methylation of the CXCR4 promoter was associated with alterations in histone modification pattern. To this end, we performed a chromatin immunoprecipitation assay to assess changes on repressive histone 3 lysine 9 trimethylation and histone 3 lysine 27 trimethylation (often associated with DNA methylation) and activating acetyl-H4 histone modifications. We found that whereas histone 3 lysine 9 trimethylation was not affected by HG exposure (Figure S2), there was a significant increase in repressive histone 3 lysine 27 trimethylation modification and reduced pan-acetyl-H4 level in HG-CD34+ stem cells (Figure 6B and 6C). Taken together, these results provide evidence that DNA methylation at the CXCR4 promoter correlates with a more-inactive chromatin conformation that better explains reduced gene expression. Indeed, when we plotted the qPCR data of CXCR4 expression against their respective DNA promoter methylation percentage and performed correlation analysis, we found that CXCR4

Figure 5. HG Increases CXCR4 promoter methylation in CD34+ stem cells. A, Schematic representation of the human CXCR4 gene. The CXCR4 gene contains a promoter region (1460 nt) and 3 exons separated by intronic sequences. The analysis of the CXCR4 promoter with MethPrimer software shows the main CpG island (from −1334 to −811 bp) within the promoter and part of the second CpG island (represented in gray). The black line in the CpG island indicates the analyzed region (from −1394 to −738 bp). B, Quantification of CpG methylation density of the CXCR4 promoter by a 2-step qPCR method in NG, HG, and exHG-CD34+ stem cells (n=8; *P<0.05 vs NG). Data are expressed as log2 fold-change (FC) over NG. C, Quantification of CXCR4 promoter methylation levels by bisulfite Sanger sequencing in NG, HG, and exHG-CD34+ stem cells (n=8; ***P<0.001 vs NG). The data, expressed as log2 FC over NG, are the result of 8 independent experiments where 10 colonies for each single sample were sequenced. D, Representative visualization of 5-bisulfite sequencing results as analyzed by QUMA software (http://quma.cdb.riken.jp/). E, Non-CpG methylation density of the CXCR4 promoter in NG, HG, and exHG-CD34+ stem cells (n=7; *P<0.05 vs NG). The data, expressed as log2 FC over NG, are the results of Methtools 2.05 software analysis after normalization on bisulfite conversion efficiency. As reported for panel C, 10 clones for each cell treatment of 8 independent experiments were sequenced. F, Representative visualization of 9-bisulfite sequencing results. Significant differences were evaluated by 1-way ANOVA followed by Newman–Keuls post-hoc analysis. CXCR4 indicates C-X-C chemokine receptor type 4; 5mCpG, methylation at the carbon 5 position of a cytosine ring in CpG (5′-cytosine-phosphate-guanine-3′); 5mCpN, methylation at the carbon 5 position of a cytosine ring in 5′-C-phosphate-nucleotide-3′; exHG, ex-high-glucose; HG, high-glucose; NG, normal-glucose; qPCR, quantitative polymerase chain reaction.

Figure 6. CXCR4 promoter methylation associates with a closer chromatin conformation. A, Schematic representation of the CXCR4 gene with mapped sequences (arrows, region I, II, and III). B and C, ChIP of the CXCR4 promoter by H3K27me3 and pan-acetyl H4 after HG exposure of CD34+ stem cells. The data after input normalization are expressed as log2 fold-change (FC) over the NG (n=3; *P<0.05 vs NG; paired t test). ChIP indicates chromatin immunoprecipitation; CXCR4, C-X-C chemokine receptor type 4; H3K27me3, trimethylation on lysine 27 of histone H3; pan-acetyl H4, acetyl-histone H4; HG, high-glucose; NG, normal glucose.
mRNA content negatively correlated with promoter methylation in CD34\(^+\) stem cells (Pearson \(r = -0.76; \ P = 0.004\); Figure 7A). Moreover, to determine whether overall epigenetic modifications reduced RNA polymerase II recruitment to the CXCR4 promoter in HG-CD34\(^+\) stem cells, we performed chromatin immunoprecipitation assay with an antibody specific for RNA polymerase II. Quantitative real-time PCR analysis of the CXCR4 gene after chromatin immunoprecipitation assay, with 3 couples of primers landing up- and downstream of the transcription start site, displayed a significant reduction of RNA polymerase II binding to the CXCR4 gene in HG-CD34\(^+\) stem cells compared with NG-CD34\(^+\) stem cells (Figure 7B).

**HG Affects Gene Expression Pattern of the “DNA Methylation Machinery” in CD34\(^+\) Stem Cells**

In mammals, the DNA methylation pattern is a fine-tuned process in which DNA methyltransferases (DNMTs), namely DNMT1, DNMT3A, and DNMT3B, and demethylation enzymes, the ten eleven translocation proteins (TETs), take part. DNMT1 associates with S-phase replication foci and acts primarily as a maintenance methyltransferase, whereas DNMT3A and DNMT3B are essential for de novo methylation.\(^{34,35}\) Based on our observations, we assessed the variation of DNMT enzymes, in HG-CD34\(^+\) stem cells. Surprisingly, both qPCR and western blot analyses revealed a significant downregulation of DNMT1 (Figure 8A, 8B, and 8C) that was counteracted by an increased expression of the DNMT3B enzyme (Figure 8D through 8F). No differences were found for DNMT3A expression (Figure S3). On the other hand, both mRNA expression levels of the TET2 and TET3 enzymes were significantly reduced (Figure 8G and 8H). Nevertheless, although these results implied an HG-induced dysregulation in the “DNA methylation machinery,” we did not find any changes in global DNA methylation level and DNMT activity in HG-CD34\(^+\) stem cells (Figure S4A and S4B), suggesting a gene-specific epigenetic modification pattern induced by hyperglycemia.

**Translation of Epigenetic Findings on CXCR4 Promoter of CD34\(^+\) Stem Cells From Diabetic Patients**

Next, to validate our in vitro observations in humans, we investigated whether methylation of the CXCR4 promoter and gene expression were altered in BM-derived CD34\(^+\) stem cells from diabetic patients. A cohort of NG-tolerant and T2DM male CAD patients (CAD/DM) undergoing bypass surgery was enrolled in the study. Importantly, the 2 groups of patients were age-matched in order to exclude any possible confounding effect of age, given that aging is associated with methylation events.\(^{36}\) Patients’ profiles and laboratory parameters are shown in Table. CD34\(^+\) stem cells isolated from sternal BM biopsies were analyzed by flow cytometry for expression of the CXCR4 receptor. As shown in Figure 9A, CD34\(^+\) stem cells from CAD-DM patients showed a lower expression of the CXCR4 receptor when compared with the normoglycemic CAD group. We then analyzed the DNA methylation density of the CXCR4 promoter by 2-step qPCR and bisulfite Sanger sequencing techniques. Consistent with our in vitro results, both methods corresponded in unveiling a significant increase...
of CpG methylation density at the level of the CXCR4 promoter in BM-derived CD34+ stem cells from CAD-DM patients (Figure 9B through 9D). Moreover, similarly to what we found in our in vitro model, we detected, although not significantly, higher non-CpG methylation levels in the CXCR4 promoter in CAD-DM patients’ CD34+ stem cells compared with the normoglycemic CAD group (Figure 9E and 9F). Again, when CXCR4 expression data were plotted against corresponding promoter methylation density data, a significant negative correlation was evident (Pearson r=−0.57; P=0.03; Figure 9G).
CXCR4 Gene Methylation in Diabetic CD34+ Stem Cells  

Vigorelli et al

**Figure 1.**

**A.** CXCR4 positive cells (%) in CAD and CAD-DM groups.

**B.** TWO-STEP qPCR for methylation status of CXCR4.

**C.** 5mCpG density and Sanger sequencing (log FC) in CAD and CAD-DM groups.

**D.** Sanger Sequencing for CAD samples.

**E.** 5mCpN density and Sanger sequencing (log FC) in CAD and CAD-DM groups.

**F.** Sanger Sequencing for CAD-DM samples.

**G.** Pearson correlation between CXCR4 expression (%) and CpG density (log %) with a P value of 0.03.

DOI: 10.1161/JAHA.118.010012  
Journal of the American Heart Association 12
Overall, our work shows that epigenetic alterations in the CXCR4 promoter methylation density of the CXCR4 stem cells of CAD and CAD-DM patients. The data are expressed as log2 fold-change (FC) over CAD. Bisulfite Sanger sequencing quantification of CXCR4 promoter methylation in CAD and CAD-DM patients. The data are expressed as log2 FC over CAD. Ten colonies for each patient’s sample were sequenced. Representative visualization of 5-bisulfite sequencing results as analyzed by QUMA software (http://quma.cdb.riken.jp/). Non-CpG methylation density of the CXCR4 promoter in CAD and CAD-DM patients. The data, expressed as log2 FC over the CAD, are the results of Methtools 2.05 software analysis after normalization on bisulfite conversion efficiency. As reported for panel C, 10 clones from each patient’s sample were sequenced. Representative visualization of 9-bisulfite sequencing results. Significant differences between sample patients were evaluated by unpaired t test (CAD, n=7; CAD-DM, n=7; *P<0.01; *P<0.05 vs CAD). Correlation analysis between percentage of CXCR4 expression and log2 percentage of CXCR4 promoter methylation (Sanger sequencing). Pearson r and P value are indicated on the graph. CXCR4 indicates C-X-C chemokine receptor type 4; 5mCpG, methylation at the carbon 5 position of a cytosine ring in CpG (5′-cytosine-phosphate-guanine-3′); 5mCpN, methylation at the carbon 5 position of a cytosine ring in 5′-C-phosphate-nucleotide-3′; CAD±DM, coronary artery disease with or without diabetes mellitus; qPCR, quantitative polymerase chain reaction.

Discussion

Overall, our work shows that epigenetic alterations in the CXCR4 promoter of human CD34+ stem cells induced by hyperglycemia have detrimental effects on their functional properties, which endure after normoglycemia recovery. This evidence has been obtained both in UCB-derived CD34+ stem cells exposed to hyperglycemia versus normoglycemia recovery as well as in BM-derived CD34+ stem cells harvested from CAD-DM patients undergoing state-of-the-art antiabetic therapy compared with age-matched normoglycemic controls. Such findings show, for the first time, that human CD34+ stem cells “memorize” the hyperglycemic environment in the form of epigenetic changes that, by contributing to the self-perpetuating alteration of gene expression, may be potentially responsible for progression of microangiopathy and cardiovascular events in T2DM subjects despite glycaemia correction. In particular, through our in vitro cell model, we provided the first experimental evidence of an epigenetic contribution to CXCR4/SDF-1 axis impairment.

Previous landmark articles demonstrated in vitro and animal models mimicking metabolic memory increases in the expression of nuclear factor kappa light chain enhancer of activated B cells p65, oxidant stress, and inflammatory genes in vascular cells. These changes, which persisted after return of NG conditions, were dependent on epigenetic histone modifications such as H3 lysine methylation. Moreover, numerous studies have shown different DNA methylation patterns between individuals with DM and matched controls in multiple target tissues that may play a substantial role in the pathophysiology of DM and its associated vascular complications. However, although the interest on DM-mediated epigenetic changes and their role in metabolic memory is growing, no data are available with regard to CD34+ stem cells. It is worth noting that the levels of circulating CD34+ stem cells have been recently proved to be an efficient clinical-grade independent biomarker of cardiovascular risk in diabetic patients, able to predict on the long-term the development or the progression of microangiopathy and cardiovascular events in T2DM. Our study adds information on epigenetic mechanisms underlying the exhaustion of reparative vascular homeostasis in DM.

Stem and progenitor cells are known to intrinsically express high levels of antioxidant enzymes that make them more resistant than mature cells to oxidative stress. The antioxidant defense capacity explains how progenitor cells can execute a regenerative program in an unfavourable oxidative environment, such as that generated by ischemia reperfusion, and inflammation and why, in our hands, CD34+ stem cells exhibited signs of metabolic exhaustion after 20 days of chronic glucose challenge. Indeed, only after this long period of metabolic overload, cells started showing increased ROS production along with reduced expression of antioxidant enzyme genes catalase and manganese superoxide dismutase. Interestingly, HG exposure also induced expression of p66shc gene in naive CD34+ stem cells. P66shc is a Src homolog and collagen homologs (shc) adaptor protein that plays a crucial role in development of diabetic vascular complications and mainly contributes to phenomenon of metabolic memory. The pathways described for its oxidant action operate on both mitochondrial and nuclear levels. In mitochondria, p66shc promotes ROS generation, whereas in the nucleus, in agreement with our findings, p66shc inhibits expression of the ROS-scavenging enzymes, catalase and manganese superoxide dismutase. In our hands, such dampening of intrinsic antioxidant mechanisms and increased ROS production resulted in CD34+ stem cell dysfunction. Specifically, HG-CD34+ stem cells displayed impaired
CXCR4 Gene Methylation in Diabetic CD34+ Stem Cells

Vigorelli et al

Introduction

Expression of chemokine receptor CXCR4 is transcriptionally regulated by DNA methylation. Analysis of this fine-tuned modulation in diseases, such as cancer and primary myelofibrosis, is responsible for the pathological phenotype of tumor cells. Our findings provide evidence that HG exposure influences per se DNA methylation of CXCR4 promoter in HG-CD34+ stem cells and negatively affects migration ability toward SDF-1α. Importantly, both the epigenetic modification and functional defects persisted after a 3-day recovery in normoglycemic conditions (exHG-CD34+). Notably, the CXCR4 promoter also displayed a significant non-CpG methylation increase. DNA methylation in mammals is predominantly reported on the cytosine of the dinucleotide sequence, CpG. However, non-CpG methylation was described in embryonic cells, and a recent study by Barres et al provided evidence that non-CpG methylation was present in skeletal muscle of T2DM subjects. Interestingly, we found that the transcription pattern of enzymes involved in DNA methylation was affected by HG exposure. In particular, DNMT3B was upregulated, thus suggesting, in agreement with Barre et al’s findings, the involvement of this enzyme in increased methylation of the CXCR4 promoter. However, further investigations will be necessary to understand the biological role of non-CpG methylation and DNMT3B on gene transcription regulation in the diabetic context.

DNA methylation and histone modification systems are known to be highly inter-related and mechanistically rely on each other for chromatin function. We found, by chromatin immunoprecipitation assay, that DNA methylation of the CXCR4 promoter was associated with a significant increase of repressive histone 3 lysine 27 trimethylation and reduced level of activating pan-acetyl-H4 in HG-CD34+ stem cells. Taken together, these findings provide evidence that HG exposure promotes a more-inactive chromatin conformation, which decreases DNA accessibility, contributing to reduction of CXCR4 expression.

We next analyzed BM-derived CD34+ stem cells of control CAD and CAD-DM patients receiving antidiabetic drugs. Remarkably, we were able to confirm the epigenetic changes observed in HG-CD34+ stem cells. In CAD-DM subjects receiving pharmacological glycemia control versus age-matched nondiabetic subjects, a significant increase of CpG methylation at the level of the CXCR4 promoter was evident and which negatively correlated with CXCR4 protein expression. Intriguingly, in line with previous data, non-CpG methylation was also increased in CAD-DM patients, although not significantly.

We acknowledge that this study, despite introducing unprecedented information, has some limitations. First, the sample size of CAD-DM patients and controls is relatively small. However, in an attempt to partially overcome this shortcoming, enrolled subjects have been selected by accurate matching for age and major risk factors. We are aware that this study does not provide a full mechanistic explanation of the link between CXCR4 methylation, mRNA expression, and cell migration impairment. We partly overcame this issue by showing that increased DNA methylation is associated with a closer chromatin structure that reduces RNA polymerase II recruitment at the CXCR4 promoter level. Further mechanistic insights will be the object of future studies.

In summary, the observations reported here show, for the first time, that CD34+ stem cells are reminiscent of diabetic milieu and that epigenetic mechanisms induced by hyperglycemia might concur to the pathogenesis of CD34+ stem cell dysfunction having direct implications on tissue homeostasis and repair in DM. We believe this study provides a proof of concept opening new perspectives in investigation on epigenetic mechanisms involved in diabetic progenitor cell dysfunction. This line of investigation may be relevant in understanding the barriers that prevent the pharmacological regression of DM cardiovascular complications despite optimal management of hyperglycemia.

Acknowledgments

We are grateful to Dr Angela Raucci for helpful discussion of the data and to Aoife Gowran, for language editing and critical comments. We also thank Dr Chiesa and the Unit of Biostatistics of Centro Cardiologico Monzino for their support in statistical data analysis.

Sources of Funding

This work was supported by Ricerca Finalizzata, Ministero della Salute (PE-2011-02348537); Bianchessi and Vigorelli’s fellowships were supported by Ricerca Finalizzata, Ministero della Salute (PE-2011-02348537).

Disclosures

None.

References

CXCR4 Gene Methylation in Diabetic CD34+ Stem Cells

Vigorelli et al


SUPPLEMENTAL MATERIAL
SUPPLEMENTAL METHODS

Global DNA Methylation

Global methylation levels of CD34\(^+\) stem cell DNA were measured using the MethylFlash Global DNA Methylation ELISA Easy kit (Epigentek, Germany) following the manufacturer's recommendations. Briefly, 100 ng of genomic DNA was used for 5-methyl cytosine (5-mC) quantitation. The input DNA was washed and incubated with a capture antibody. The wells were then washed, and detection antibody was applied. Use of enhancer solution and development solution created a color change proportional to the quantity of 5-mC content, and the samples were read colorimetrically on an automated plate reader at 450-nm absorbance. The use of a standard curve enabled the quantification of 5-mC based on absorbance measurements. The data were expressed 5-mC\% (5-mC/total DNA (A+G+C+T)).

DNMT Activity Assay

Nuclear extracts of CD34\(^+\) stem cells were prepared by EpiQuik™ Nuclear Extraction Kit (Epigentek, Germany), and the total DNMT activity of nuclear extracts was detected according to the manufacturer's protocol (EpiQuik™ DNA Methyltransferase Activity/Inhibition Assay Kit, Epigentek, Germany), the absorbance of samples taken from each well was measured on a microplate reader (Synergy HT, Bio-Tek) at 450-nm. The DNMT activity was calculated and expressed using the following formula: (Sample OD – Blank OD) / (protein amount (ug) x hour) x1000
Table S1. Antibody List.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Provider</th>
<th>Clone or antitbody ID</th>
<th>WB Dilution</th>
<th>ChIP [μL]</th>
<th>MWT. (kDa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histone H4ac (pan-acetyl) antibody (pAb)</td>
<td>Active Motif</td>
<td>39243</td>
<td>1:5000</td>
<td>5 μL</td>
<td>25</td>
</tr>
<tr>
<td>Anti-Histone H3 (tri methyl K9) antibody - ChIP Grade</td>
<td>QIAGEN</td>
<td>GAH-6204</td>
<td>1:1000</td>
<td>5 μg</td>
<td>62</td>
</tr>
<tr>
<td>Anti-Histone H3K27me antibody - ChIP Grade</td>
<td>Abcam</td>
<td>ab6002</td>
<td>1:1000</td>
<td>5 μg</td>
<td>62</td>
</tr>
<tr>
<td>Human RNA Polymerase II ChampionChip™</td>
<td>QIAGEN</td>
<td>GAH-111</td>
<td>1:5000</td>
<td>2 μg/ml</td>
<td>25</td>
</tr>
<tr>
<td>MnSOD, Rabbit</td>
<td>Abcam</td>
<td>ab13533</td>
<td>1:5000</td>
<td>2 μg/ml</td>
<td>25</td>
</tr>
<tr>
<td>CAT, Rabbit</td>
<td>Abcam</td>
<td>ab52477</td>
<td>1:1000</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>p53, Rabbit</td>
<td>Abcam</td>
<td>ab24787</td>
<td>1:1000</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>p-Akt, Rabbit</td>
<td>Cell Signaling</td>
<td>9271</td>
<td>1:1000</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Akt, Rabbit</td>
<td>Cell Signaling</td>
<td>9272</td>
<td>1:1000</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>DNMT1, Rabbit</td>
<td>Abcam</td>
<td>ab19905</td>
<td>1:200</td>
<td>184-176-144</td>
<td></td>
</tr>
<tr>
<td>DNMT3B, Monoclonal Rabbit</td>
<td>Cell Signaling</td>
<td>D7070</td>
<td>1:500</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td>GAPDH, Rabbit</td>
<td>Cell Signaling</td>
<td>14C10</td>
<td>1:2000</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Anti-β-Actin Peroxidase antibody, Monoclonal Mouse</td>
<td>Sigma Aldrich</td>
<td>AC-15</td>
<td>1:10000</td>
<td>42</td>
<td></td>
</tr>
</tbody>
</table>
### Table S2. Primer List.

<table>
<thead>
<tr>
<th>c-DNA</th>
<th>Name</th>
<th>Sequence 5’→ 3’</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MaSOD fw</strong></td>
<td>CACCA[GAGCAAGCAACCA</td>
<td></td>
</tr>
<tr>
<td><strong>MaSOD rv</strong></td>
<td>CTGTCAAGGACCATAAGTGCA</td>
<td></td>
</tr>
<tr>
<td><strong>CAT fw</strong></td>
<td>CTGAGGCTGAGGAGGTAA</td>
<td></td>
</tr>
<tr>
<td><strong>CAT rv</strong></td>
<td>TGCTGGTCTGAAAGAATGGA</td>
<td></td>
</tr>
<tr>
<td><strong>p66hcf fw</strong></td>
<td>AGTACACTCACTCGGAAATGA</td>
<td></td>
</tr>
<tr>
<td><strong>p66hcf rv</strong></td>
<td>GGGCGCCAGGAGTGAAG</td>
<td></td>
</tr>
<tr>
<td><strong>DNMT1 fw</strong></td>
<td>GTCAAAACAAAGAACCACACC</td>
<td></td>
</tr>
<tr>
<td><strong>DNMT1 rv</strong></td>
<td>GAATTCTGTTCTTCTCATTCT</td>
<td></td>
</tr>
<tr>
<td><strong>DNMT3A fw</strong></td>
<td>GTAACCTTCGCGATAGAAGCAG</td>
<td></td>
</tr>
<tr>
<td><strong>DNMT3A rv</strong></td>
<td>CTGCATTATGGGGTTTCTCCTC</td>
<td></td>
</tr>
<tr>
<td><strong>DNMT3B fw</strong></td>
<td>AAACCCCAACACACACCGA</td>
<td></td>
</tr>
<tr>
<td><strong>DNMT3B rv</strong></td>
<td>TTTCGGTCTGATCTTCTAC</td>
<td></td>
</tr>
<tr>
<td><strong>TET2 fw</strong></td>
<td>AGAACGAGGCTGCAAGGACT</td>
<td></td>
</tr>
<tr>
<td><strong>TET2 rv</strong></td>
<td>GAGGTGATGCGTCGAGAGTTG</td>
<td></td>
</tr>
<tr>
<td><strong>TET3 fw</strong></td>
<td>GGAACAAACCGAAGAAGGAGA</td>
<td></td>
</tr>
<tr>
<td><strong>TET3 rv</strong></td>
<td>CTACGGGAGGACCTACGCGA</td>
<td></td>
</tr>
<tr>
<td><strong>CXCR4 fw</strong></td>
<td>AGCAGGGAGCAGCGAGTGGC</td>
<td></td>
</tr>
<tr>
<td><strong>CXCR4 rv</strong></td>
<td>CCTCGGTTATGCTGTTGGAATGTA</td>
<td></td>
</tr>
</tbody>
</table>

### ChIP Assay

| Region1 CXCR4 fw | CCCCCAGTTCCTCACCTAA |
| Region1 CXCR4 rv | GCAAATAGCCCGAGGAGAT |
| Region2 CXCR4 fw | CGGTTAACGTCAGTG | |
| Region2 CXCR4 rv | AAGGAACAGACGCACCTC |
| Region3 CXCR4 fw | CACCTGTGGGAGAGAGC |
| Region3 CXCR4 rv | GCCCAAGTTTATTTTCTC |
Figure S1. Flow cytometric quantification of ROS production in HG and exHG-CD34+ stem cells.

The data are reported as log$_2$ fold-change (FC) of MFI over control (NG). ($n=4$; *$p<0.05$ vs NG; 1-way ANOVA followed by Newman-Keuls post hoc analysis). exHG indicates ex-high glucose; HG, high glucose; MFI, mean fluorescence intensity; NG, normal glucose; ROS, radical oxygen species.
Figure S2. A, Schematic representation of the CXCR4 gene with mapped sequences (arrows, region I, II and III). B, ChIP analysis of the CXCR4 promoter for H3K9me3 modification after hyperglycaemia exposure of CD34+ stem cells.

The data, after input normalization are expressed as log₂ fold change over NG (n=3; paired t-test). ChIP indicates chromatin immunoprecipitation; CXCR4, C-X-C chemokine receptor type 4; H3K9me3, trimethylation on lysine 9 of histone H3; HG, high glucose; NG, normal glucose.
Figure S3. Analysis of DNMT3A, expression in CD34+ stem cells by qPCR.

The data expressed as log₂ fold change over NG are from at least 6 independent experiments (NG vs HG; paired t-test). DNMT3A indicates DNA methyltransferase 3A; HG, high glucose; NG, normal glucose.
Figure S4. A, Effect of HG exposure on global 5-mC methylation level in CD34+ stem cells. The data are expressed as 5-mC% (5-mC/total DNA (A+G+C+T)). B, DNMT activity in HG-CD34+ stem cells after HG exposure.

The DNMT activity was calculated and expressed using the following formula: (Sample OD – Blank OD) / (protein amount (ug) x hour) x1000. The data are from at least 3 independent experiments (NG vs HG; paired t-test). DNMT indicates DNA methyltransferase; HG, high glucose; NG, normal glucose; OD, optical density.